Bayer's alternative site glucose tests gain FDA OK:
This article was originally published in Clinica
The US FDA has approved Bayer Diagnostics' line of alternate site glucose self-test monitors, which include the Glucometer Elite, Glucometer Elite XL and Glucometer DEX/DEX 2 systems for use on the forearm, palm, abdomen and thigh. Alternate site testing allows patients to draw blood from different parts of the body, to reduce the pain associated with using the site each day. The firm, of Tarrytown, New York, says that 9 million of the 17 million US diabetics self-monitor glucose levels.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.